Skip to main content
. 2018 Sep 20;7(10):144. doi: 10.3390/cells7100144

Figure 1.

Figure 1

Effects of Intralipid® (lipid emulsion, LE) and SB216763 alone and in combination on the doxorubicin (DXR)-induced decreased viability of H9c2 rat cardiomyoblasts as determined by the MTT assay; the results are expressed as a percentage of the untreated control group (100%). (A) Treatment with DXR (N = 6) at various concentrations for 24 h. (B) Pretreatment with 20% LE (N = 12; 0.125%, 0.25%, 0.75%, 2%) for 1 h followed by DXR (10−5 M) for 24 h. (C) Treatment with LE (N = 6) alone at 0.125%, 0.25%, 0.75%, and 2% for 25 h. (D) Cells (N = 6) were treated with DXR alone for 24 h; treated with SB216763 (5 × 10−6 M) for 1 h or LE (0.25%) for 1 h followed by DXR for 24 h; pretreated with SB216763 (5 × 10−6 M) for 1 h, LE (0.25%) for 1 h, and then DXR for 24 h; or treated with SB216763 (5 × 10−6 M) alone for 26 h. Data are presented as the mean ± SD. A and C: * p < 0.001 versus control. † p < 0.001 versus DXR (10−6 M). # p < 0.001 versus DXR (3 × 10−6 M). B and D: * p < 0.001 versus control. † p < 0.001 versus DXR alone.